All In Biotech

Drug Trial Radar · NCT00947141

Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)

Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring

Last checked: Nov 19, 2026Latest source record: Oct 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Feb 2003

Primary completion

Dec 2011

Study completion Feb 2013

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to determine: a) whether those patients with 'low level' viral load results (between 200 and 3,000 copies/ml) could be monitored as opposed to starting preemptive therapy with valganciclovir, ganciclovir and/or foscarnet; b) whether those patients with 'high level' viral load results (above 3,000 copies/ml) could stop preemptive therapy earlier, thus maximising the benefits of therapy and minimising its risks.

Conditions

  • Viraemia

Interventions

  • ganciclovir (start when CMV PCR >200copies / ml x2)Drug

    Group A: Start ganciclovir when CMV PCR \>200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions. Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B

  • Monitor (Treatment starts when CMV PCR >3,000 copies / ml)Other

    Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions. Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B

  • Stop treatment when 2 levels CMV PCR <3,000 copies / mlDrug

    Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions. Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B

  • Monitor (Treatment stops CMV PCR <200 copies / ml x2)Other

    Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions. Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group A # with low level of CMV who develop a viral load > 3000 copies/ml & Group B # who develop a 2nd episode of a viral load above 3000 copies/ml after therapy stopped.Time frame: At study completion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond Street

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.